Merck KGaA (MRK) Given Buy Rating at DZ Bank

Merck KGaA (FRA:MRK)‘s stock had its “buy” rating reiterated by investment analysts at DZ Bank in a research note issued on Monday.

Other analysts also recently issued reports about the company. Oddo Bhf set a €125.00 ($154.32) price objective on Merck KGaA and gave the stock a “buy” rating in a report on Friday, October 27th. Kepler Capital Markets set a €115.00 ($141.98) price objective on Merck KGaA and gave the stock a “buy” rating in a report on Monday, November 6th. equinet set a €112.00 ($138.27) price objective on Merck KGaA and gave the stock a “buy” rating in a report on Friday, November 3rd. Berenberg Bank set a €116.00 ($143.21) price objective on Merck KGaA and gave the stock a “buy” rating in a report on Thursday, November 9th. Finally, Warburg Research set a €115.00 ($141.98) price objective on Merck KGaA and gave the stock a “buy” rating in a report on Thursday, November 9th. Eleven investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of €107.57 ($132.80).

Merck KGaA (FRA:MRK) traded up €0.90 ($1.11) during mid-day trading on Monday, hitting €82.00 ($101.23). The stock had a trading volume of 549,502 shares. The firm has a market cap of $10,660.00 and a P/E ratio of 19.20. Merck KGaA has a 1-year low of €80.50 ($99.38) and a 1-year high of €115.00 ($141.98).

WARNING: “Merck KGaA (MRK) Given Buy Rating at DZ Bank” was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international copyright law. The legal version of this report can be viewed at https://ledgergazette.com/2018/02/12/merck-kgaa-mrk-given-buy-rating-at-dz-bank.html.

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply